Karen J. Wilson, CPA

Ms. Wilson is a strategic biopharmaceutical finance executive and board member with more than 30 years of industry and leadership experience in life science companies across finance, strategy and risk management.  She is currently an independent Director and Chairperson of the Audit Committee for Elicio Therapeutics (ELTX) (formerly Angion Biomedica) and LAVA Therapeutics (LVTX). She previously served on the board of Vaxart, Inc. (VXRT).  She also previously served as Senior Vice President of Finance at Jazz Pharmaceuticals plc (JAZZ), an international biopharmaceutical company.  Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley.